Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 9 , Pages 879-883 , September 2009

Trichotillomania Across the Life Span

  • Michael H. Bloch, M.D., M.S.

      Affiliations

    • Corresponding Author InformationCorrespondence to Michael Bloch, M.D., Child Study Center, Yale University School of Medicine, PO Box 2070900, New Haven, CT 06520

,Accepted 20 April 2009.

References 

  1. Christenson GA , Mackenzie TB , Mitchell JE . Characteristics of 60 adult chronic hair pullers . Am J Psychiatry . 1991;148:365–370
  2. Bloch MH , Landeros-Weisenberger A , Dombrowski P , et al.   Systematic review: pharmacological and behavioral treatment for trichotillomania . Biol Psychiatry . 2007;62:839–846
  3. Woods DW , Flessner CA , Franklin ME , et al.   The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization . J Clin Psychiatry . 2006;67:1877–1888
  4. Franklin ME , Flessner CA , Woods DW , et al.   The Child and Adolescent Trichotillomania Impact Project: descriptive psychopathology, comorbidity, functional impairment, and treatment utilization . J Dev Behav Pediatr . 2008;29:493–500
  5. Bruce TO , Barwick LW , Wright HH . Diagnosis and management of trichotillomania in children and adolescents . Paediatr Drugs . 2005;7:365–376
  6. Tolin DF , Diefenbach GJ , Flessner CA , et al.   The trichotillomania scale for children: development and validation . Child Psychiatry Hum Dev . 2008;39:331–349
  7. Keuthen NJ , O'Sullivan RL , Ricciardi JN , et al.   The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses . Psychother Psychosom . 1995;64:141–145
  8. Tolin DF , Franklin ME , Diefenbach GJ , Anderson E , Meunier SA . Pediatric trichotillomania: descriptive psychopathology and an open trial of cognitive behavioral therapy . Cogn Behav Ther . 2007;36:129–144
  9. Grant JE , Odlaug B , Kim SW . N-acetylcysteine, a glutamate modulating agent, in the treatment of trichotillomania: a double-blind, placebo-controlled study . Arch Gen Psychiatry . 2009;66:756–763

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.This article was reviewed under and accepted by Deputy Editor John T. Walkup, M.D.The author thanks the National Institute of Mental Health support of the Yale Child Study Center Research Training Program, the National Institute of Health Loan Repayment Program, and the APIRE/Eli Lilly Psychiatric Research Fellowship. The author also thanks Kaitlyn E. Panza, B.A., for help in revising this article.

PII: S0890-8567(09)60143-X

doi: 10.1097/CHI.0b013e3181ae09f3

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 9 , Pages 879-883 , September 2009

Article Tools

* Image Usage & Resolution